{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T08:02:58Z","timestamp":1773302578663,"version":"3.50.1"},"reference-count":36,"publisher":"Archives of Pathology and Laboratory Medicine","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,9,1]]},"abstract":"<jats:sec>\n                    <jats:title>Context.\u2014<\/jats:title>\n                    <jats:p>Prostate cancer antigen 3 (PCA3) is a noncoding RNA that is highly overexpressed in prostate cancer (PCa) tissue and excreted in urine in patients with PCa.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective.\u2014<\/jats:title>\n                    <jats:p>To assess the clinical utility of urinary PCA3 in men at risk of PCa.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design.\u2014<\/jats:title>\n                    <jats:p>We retrospectively reviewed a cohort of 271 men (median age, 63 years) with elevated prostate-specific antigen (PSA), and\/or strong family history, and\/or abnormal digital rectal examination findings. Diagnostic sensitivity, specificity, positive and negative predictive values (PPV, NPV), positive and negative likelihood ratios (LR+, LR\u2212), and diagnostic odds ratio (DOR), and area under the receiver-operating characteristic curves (AUC) were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.\u2014<\/jats:title>\n                    <jats:p>PCA3 score was a significant predictor of prostate biopsy outcome (P &amp;lt; .001). A PCA3 score of 30 was the optimal cutoff for our study cohort, with a diagnostic sensitivity of 72.7%, specificity of 67.5%, PPV of 47.1%, NPV of 86.2%, LR+ of 2.24, LR\u2212 of 0.40, and DOR of 5.55. At this cutoff score, the PCA3 assay could avoid 57.4% of unnecessary invasive biopsies in the overall study cohort and 70.3% in the subgroup with PSA level in the \u201cgray zone\u201d (4\u201310 ng\/mL). A logistic regression algorithm combining PCA3 with PSA increased the AUC from 0.571 for PSA-only to 0.729 (P &amp;lt; .001). The logistic combined marker gained the ability to discriminate low-grade from high-grade cancers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions.\u2014<\/jats:title>\n                    <jats:p>Our data suggest that PCA3 improves the diagnostic sensitivity and specificity of PSA and that the combination of PCA3 with PSA gives better overall performance in identification of PCa than serum PSA alone in the high-risk population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5858\/arpa.2017-0185-oa","type":"journal-article","created":{"date-parts":[[2018,3,16]],"date-time":"2018-03-16T08:59:27Z","timestamp":1521190767000},"page":"1106-1112","source":"Crossref","is-referenced-by-count":16,"title":["Combination of Prostate Cancer Antigen 3 and Prostate-Specific Antigen Improves Diagnostic Accuracy in Men at Risk of Prostate Cancer"],"prefix":"10.5858","volume":"142","author":[{"given":"Liyun","family":"Cao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi Hyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Ning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beverly C.","family":"Handy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth A.","family":"Wagar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing H.","family":"Meng","sequence":"additional","affiliation":[{"name":"From the Departments of Laboratory Medicine (Drs Cao, Handy, Wagar, and Meng) and Biostatistics (Drs Lee and Ning), The University of Texas MD Anderson Cancer Center, Houston, Texas. Dr Cao is now at the Division of Laboratory Medicine, Department of Pathology, the University of Alabama at Birmingham."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3906","published-online":{"date-parts":[[2018,3,16]]},"reference":[{"issue":"1","key":"2020081220442254300_i1543-2165-142-9-1106-b01","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21332","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"2020081220442254300_i1543-2165-142-9-1106-b02","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s00345-012-0824-2","article-title":"Prostate cancer epidemiology in the United States","volume":"30","author":"Brawley","year":"2012","journal-title":"World J Urol"},{"issue":"4","key":"2020081220442254300_i1543-2165-142-9-1106-b03","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/nrc2351","article-title":"Prostate-specific antigen and prostate cancer: prediction, detection and monitoring","volume":"8","author":"Lilja","year":"2008","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"2020081220442254300_i1543-2165-142-9-1106-b04","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1159\/000472983","article-title":"Clinical behavior of prostatic specific antigen and prostatic acid phosphatase: a comparative study","volume":"14","author":"Morote Robles J, Ruibal Morell A, Palou Redorta J, de Torres Mateos JA, Soler Rosello A","year":"1988","journal-title":"Eur Urol"},{"issue":"2","key":"2020081220442254300_i1543-2165-142-9-1106-b05","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3322\/caac.20066","article-title":"American Cancer Society guideline for the early detection of prostate cancer: update 2010","volume":"60","author":"Wolf","year":"2010","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"2020081220442254300_i1543-2165-142-9-1106-b06","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S0022-5347(17)35233-3","article-title":"Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men","volume":"151","author":"Catalona","year":"1994","journal-title":"J Urol"},{"issue":"3","key":"2020081220442254300_i1543-2165-142-9-1106-b07","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.eururo.2005.04.015","article-title":"Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng\/ml: systematic review and meta-analysis [discussion in","volume":"48","author":"Roddam","year":"2005","journal-title":"Eur Urol"},{"issue":"7","key":"2020081220442254300_i1543-2165-142-9-1106-b08","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/j.1525-1497.2006.00464.x","article-title":"The impact of a suspicious prostate biopsy on patients' psychological, socio-behavioral, and medical care outcomes","volume":"21","author":"Fowler","year":"2006","journal-title":"J Gen Intern Med"},{"issue":"3","key":"2020081220442254300_i1543-2165-142-9-1106-b09","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1464-410X.2011.10926.x","article-title":"Complications following prostate needle biopsy requiring hospital admission or emergency department visits: experience from 1000 consecutive cases","volume":"110","author":"Pinkhasov","year":"2012","journal-title":"BJU Int"},{"issue":"22","key":"2020081220442254300_i1543-2165-142-9-1106-b10","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1056\/NEJMoa031918","article-title":"Prevalence of prostate cancer among men with a prostate-specific antigen level &lt; or =4.0 ng per milliliter","volume":"350","author":"Thompson","year":"2004","journal-title":"N Engl J Med"},{"issue":"6","key":"2020081220442254300_i1543-2165-142-9-1106-b11","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.eururo.2013.12.062","article-title":"Overdiagnosis and overtreatment of prostate cancer","volume":"65","author":"Loeb","year":"2014","journal-title":"Eur Urol"},{"issue":"1","key":"2020081220442254300_i1543-2165-142-9-1106-b12","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00345-007-0145-z","article-title":"Overdiagnosis and overtreatment of early detected prostate cancer","volume":"25","author":"Bangma","year":"2007","journal-title":"World J Urol"},{"issue":"23","key":"2020081220442254300_i1543-2165-142-9-1106-b13","first-page":"5975","article-title":"DD3: a new prostate-specific gene, highly overexpressed in prostate cancer","volume":"59","author":"Bussemakers","year":"1999","journal-title":"Cancer Res"},{"issue":"1","key":"2020081220442254300_i1543-2165-142-9-1106-b14","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0302-2838(03)00201-X","article-title":"DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer [discussion in","volume":"44","author":"Hessels","year":"2003","journal-title":"Eur Urol"},{"issue":"9","key":"2020081220442254300_i1543-2165-142-9-1106-b15","first-page":"2695","article-title":"DD3(PCA3), a very sensitive and specific marker to detect prostate tumors","volume":"62","author":"de Kok","year":"2002","journal-title":"Cancer Res"},{"key":"2020081220442254300_i1543-2165-142-9-1106-b16","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13046-015-0127-8","article-title":"PCA3 in prostate cancer and tumor aggressiveness detection on 407 high-risk patients: a National Cancer Institute experience","volume":"34","author":"Merola","year":"2015","journal-title":"J Exp Clin Cancer Res"},{"key":"2020081220442254300_i1543-2165-142-9-1106-b17","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/978-94-017-7215-0_17","article-title":"Urinary prostate cancer antigen 3 as a tumour marker: biochemical and clinical aspects","volume":"867","author":"Schmid","year":"2015","journal-title":"Adv Exp Med Biol"},{"key":"2020081220442254300_i1543-2165-142-9-1106-b18","doi-asserted-by":"crossref","first-page":"25776","DOI":"10.1038\/srep25776","article-title":"Evaluation of prostate cancer antigen 3 for detecting prostate cancer: a systematic review and meta-analysis","volume":"6","author":"Cui","year":"2016","journal-title":"Sci Rep"},{"issue":"12","key":"2020081220442254300_i1543-2165-142-9-1106-b19","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1373\/clinchem.2015.246280","article-title":"STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies","volume":"61","author":"Bossuyt","year":"2015","journal-title":"Clin Chem"},{"issue":"5","key":"2020081220442254300_i1543-2165-142-9-1106-b20","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nrurol.2009.40","article-title":"The use of PCA3 in the diagnosis of prostate cancer","volume":"6","author":"Hessels","year":"2009","journal-title":"Nat Rev Urol"},{"issue":"2","key":"2020081220442254300_i1543-2165-142-9-1106-b21","first-page":"627","article-title":"Receiver operating characteristic (ROC) curve analysis for medical diagnostic test evaluation","volume":"4","author":"Hajian-Tilaki","year":"2013","journal-title":"Caspian J Intern Med"},{"issue":"11","key":"2020081220442254300_i1543-2165-142-9-1106-b22","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1111\/j.1464-410X.2011.10584.x","article-title":"A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy","volume":"109","author":"Auprich","year":"2012","journal-title":"BJU Int"},{"issue":"36","key":"2020081220442254300_i1543-2165-142-9-1106-b23","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1200\/JCO.2013.52.8505","article-title":"Can urinary PCA3 supplement PSA in the early detection of prostate cancer?","volume":"32","author":"Wei","year":"2014","journal-title":"J Clin Oncol"},{"issue":"4","key":"2020081220442254300_i1543-2165-142-9-1106-b24","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/j.juro.2007.11.038","article-title":"PCA3: a molecular urine assay for predicting prostate biopsy outcome","volume":"179","author":"Deras","year":"2008","journal-title":"J Urol"},{"key":"2020081220442254300_i1543-2165-142-9-1106-b25","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.cca.2014.04.025","article-title":"Real-time PCR PCA3 assay is a useful test measured in urine to improve prostate cancer detection","volume":"435","author":"Foj","year":"2014","journal-title":"Clin Chim Acta"},{"issue":"6","key":"2020081220442254300_i1543-2165-142-9-1106-b26","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1016\/j.juro.2011.01.075","article-title":"Clinical evaluation of the PCA3 assay in guiding initial biopsy decisions","volume":"185","author":"de la Taille","year":"2011","journal-title":"J Urol"},{"issue":"9","key":"2020081220442254300_i1543-2165-142-9-1106-b27","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1158\/1078-0432.CCR-12-3283","article-title":"Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study","volume":"19","author":"Lin","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2020081220442254300_i1543-2165-142-9-1106-b28","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/pros.21457","article-title":"Chronic prostatitis does not influence urinary PCA3 score","volume":"72","author":"Vlaeminck-Guillem","year":"2012","journal-title":"Prostate"},{"issue":"1","key":"2020081220442254300_i1543-2165-142-9-1106-b29","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.juro.2013.02.018","article-title":"PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical study","volume":"190","author":"Gittelman","year":"2013","journal-title":"J Urol"},{"issue":"1","key":"2020081220442254300_i1543-2165-142-9-1106-b30","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.eururo.2015.04.039","article-title":"Urine TMPRSS2:ERG plus PCA3 for individualized prostate cancer risk assessment","volume":"70","author":"Tomlins","year":"2016","journal-title":"Eur Urol"},{"issue":"5","key":"2020081220442254300_i1543-2165-142-9-1106-b31","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/j.juro.2008.01.013","article-title":"PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance [discussion in","volume":"179","author":"Nakanishi","year":"2008","journal-title":"J Urol"},{"issue":"1","key":"2020081220442254300_i1543-2165-142-9-1106-b32","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.eururo.2010.10.024","article-title":"Critical assessment of preoperative urinary prostate cancer antigen 3 on the accuracy of prostate cancer staging","volume":"59","author":"Auprich","year":"2011","journal-title":"Eur Urol"},{"issue":"1","key":"2020081220442254300_i1543-2165-142-9-1106-b33","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/pros.21032","article-title":"Predictive value of PCA3 in urinary sediments in determining clinico-pathological characteristics of prostate cancer","volume":"70","author":"Hessels","year":"2010","journal-title":"Prostate"},{"issue":"3","key":"2020081220442254300_i1543-2165-142-9-1106-b34","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/j.1464-410X.2011.10377.x","article-title":"The relationship between Prostate CAncer gene 3 (PCA3) and prostate cancer significance","volume":"109","author":"van Poppel","year":"2012","journal-title":"BJU Int"},{"issue":"5","key":"2020081220442254300_i1543-2165-142-9-1106-b35","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.eururo.2008.06.071","article-title":"Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy","volume":"54","author":"Haese","year":"2008","journal-title":"Eur Urol"},{"issue":"4","key":"2020081220442254300_i1543-2165-142-9-1106-b36","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.juro.2010.11.072","article-title":"Urinary PCA3 score predicts prostate cancer multifocality","volume":"185","author":"Vlaeminck-Guillem","year":"2011","journal-title":"J Urol"}],"container-title":["Archives of Pathology &amp; Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/meridian.allenpress.com\/aplm\/article-pdf\/142\/9\/1106\/1449528\/arpa_2017-0185-oa.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/aplm\/article-pdf\/142\/9\/1106\/1449528\/arpa_2017-0185-oa.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T19:34:22Z","timestamp":1764790462000},"score":1,"resource":{"primary":{"URL":"https:\/\/aplm.kglmeridian.com\/view\/journals\/arpa\/142\/9\/article-p1106.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,16]]},"references-count":36,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2018,3,16]]},"published-print":{"date-parts":[[2018,9,1]]}},"URL":"https:\/\/doi.org\/10.5858\/arpa.2017-0185-oa","relation":{},"ISSN":["0003-9985","1543-2165"],"issn-type":[{"value":"0003-9985","type":"print"},{"value":"1543-2165","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,16]]}}}